Monoclonal Antibody Therapy Companies

FDA approves Regeneron's REGN-COV 2 (casirivimab/imdevimab) for the prevention of COVID-19 in high-risk adults and adolescents significant approval expands access to monoclonal antibody prophylaxis for vulnerable individuals, offering protection against COVID-19 infection.

Eli Lilly receives breakthrough designation for bamlanivimab and etesevimab combination for early treatment of mild-to-moderate COVID-19 FDA designation fast-tracks development and review of the therapy, highlighting its potential for early intervention against the virus.

GlaxoSmithKline enters a collaboration with iTeos Therapeutics to develop EOS-448, an anti-TIGIT monoclonal antibody for cancer treatment partnership combines GSK's expertise in immuno-oncology with iTeos' innovative technology, aiming to bring promising new cancer therapies to patients.

Amgen expands Repatha (evolocumab) indication to include treatment of heterozygous familial hypercholesterolemia (HeFH) in children aged 10 years and older approval broadens access to effective cholesterol-lowering therapy for young patients with this inherited condition.

List of Monoclonal Antibody Therapy Key Companies in the Market

• Sigma-Aldrich Co. LLC


• Sanofi


• Pfizer Inc


• Novartis AG


• Merck Kae


• Johnson & Johnson


• GlaxoSmithKline Plc GlaxoSmithKline Plc


• GenScript,


• AbbVie Inc


• Amgen Inc


• Bayer AG


• Biogen Inc


• Bristol


• Myers Squibb Company


• Hoffmann-La Roche Ltd